1. Global Markets for Marine-Derived Pharmaceuticals
Published:October 2011
No.Of pages:180
Price:US $ 4850
INTRODUCTION
The search for bioactive metabolites from marine microbes has only just begun”—David
Newman, D. Phil, and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide is
Turning (2006)
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the global
marine-derived pharmaceutical market, including its growth potential during the period of
2011 to 2016. Our key objective is to present a comprehensive analysis of marine life and
technology as they relate to pharmaceutical applications and to forecast this market’s future
direction.
REASONS FOR DOING THIS STUDY
Our understanding of marine life only began during the last half of the 20th century. The
first marine discovery that led to a pharmaceutical drug began in the 1950s when chemists
Bergmann and Feeney isolated nucleosidic compounds from the Caribbean sponge
Cryptotethya crypta. Marine drugs on the market today can be traced to this discovery
(e.g., anticancer drug cytarabine).
While marine life is used for many applications, including food and industrial processing, its
use in the pharmaceutical industry has just begun. Marine life offers a complex and diverse
genetic resource unavailable on land, which has led to the exploration of the oceans to find
new tests and cures for illnesses. Entire classes of antibiotics desperately needed for a world
surviving on relatively few antibiotics, which people are becoming resistant to, could be
found in just a few marine samples.
The report Global Markets for Marine-Derived Pharmaceuticals describes the potential of
marine research and its growth prospects. It is estimated that marine-derived drugs will
essentially double in number from 2011 to 2016. Because marine-derived drugs already
account for a few powerful drugs, this area of the drug industry has already generated
billions of dollars to date.
SCOPE OF REPORT
The scope of this study encompasses research organizations, the U.S. government chiefly in
the form of the National Cancer Institute (NCI), and companies that develop or help in the
development process of pharmaceuticals derived from marine life. Included are extensive
descriptions, perspectives, and predictive information, including forecasts of growth over the

2. next 5 years. Technological issues, including the latest trends, are discussed.
INTENDED AUDIENCE
In this report, marine-derived pharmaceuticals are described in terms of their history in
medicine, technology types and categories, research organizations, major companies,
impact on the pharmaceutical market, applications, current market values, growth potential,
and significant trends. This study will be of interest to non-profits and the government
sector as well as the biotechnology and pharmaceutical industries and related life science,
analytics, drug discovery, and diagnostic test manufacturing companies as well as all those
interested in or actively working in drug and imaging agent research and investors in all of
the above.
METHODOLOGY
BCC presents an analysis of the types of technologies, applications, and therapeutic areas
representing the financial value of marine-derived pharmaceuticals. Estimated values are
based on actual aggregate sales for the years discussed. Information, in general, is
compiled through a combination of primary and secondary research, including annual
reports and interviews with company and government officials as well as experts in
academia.
INFORMATION SOURCES
BCC’s analysis includes the review of more than 50 companies and information from
financial and trade publications as well as the U.S. Food and Drug Administration (FDA).
Included were pharmaceutical and biotechnology companies as well as support companies
to them.
ABOUT THE AUTHOR
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature. She
acquired experience as a healthcare journalist, including working for John Wiley & Sons for
years as a print reporter, before serving as a research analyst in a small market research
firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area
of North Carolina. Before joining that firm, Kim published two reports on emerging and
established diagnostics and therapeutics for benign and cancerous breast disease.|
Table Of Contents
Chapter- 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY
INFORMATION SOURCES

3. ABOUT THE AUTHOR
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter- 2: EXECUTIVE SUMMARY
INVESTMENT AND PATH FORWARD
KEY DRIVERS
KEY CHALLENGES
KEY TRENDS
INVESTMENT LANDSCAPE
Chapter- 3: OVERVIEW
HISTORY OF MARINE DRUGS
MAJOR CATEGORIES OF MARINE DRUGS
Chapter- 4: MARKET LANDSCAPE
COMMERCIALIZED MARINE LIFE DRUGS BY TYPE
PHARMACEUTICAL MARKET IN GENERAL
MARINE-DERIVED DRUG LANDSCAPE
COMMERCIALIZATION LANDSCAPE BY 2016
MECHANISMS OF ACTION
MARINE DRUG CULTIVATION
REGULATORY ENVIRONMENT
PATENTS
MARINE DRUG DEVELOPMENT: AREAS OF FOCUS TO WATCH
MARINE DRUG DEVELOPMENT RESEARCH
DISEASES/CONDITIONS MOST OFTEN TREATED WITH MARINE DRUGS
Chapter- 5: COMPANY PROFILES
ABBOTT LABORATORIES
AFFIRIS AG
AKER BIOMARINE ASA
ALGENICS
APHIOS CORP.
APP PHARMACEUTICALS
ARCTICZYMES
ASKA PHARMACEUTICAL CO., LTD.
ASTELLAS (AGENSYS, INC.)
AQUAPHARM BIODISCOVERY, LTD.
AZUR PHARMA
BASF SE
BAYER INNOVATION
BEDFORD LABORATORIES
BIOSYN CORP.
BIOVEST INTERNATIONAL, INC.
BTG INTERNATIONAL, LTD.
CATABASIS PHARMACEUTICALS, INC.
CELLDEX THERAPEUTICS
CENTOCOR ORTHO BIOTECH
COGNETIX, INC.

4. COMENTIS
CYANOTECH CORP.
EISAI CO., LTD.
ELAN CORP. (ELAN PHARMACEUTICALS, INC.)
EUROPHARMA, INC.
GENZYME
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE
GLYCOMAR, LTD.
GILEAD SCIENCES
HOSPIRA, INC.
IMMUNOPHOTONICS
INTEGRIN ADVANCED BIOSYSTEMS
INTERMED DISCOVERY GMBH
INTRACEL
KLINIPHARM GMBH
MAGELLAN BIOSCIENCE GROUP, INC
MARINE POLYMER TECHNOLOGIES, INC.
MARINOVA PTY, LTD.
MARTEK BIOSCIENCES CORP.
MEDIMETRIKS PHARMACEUTICALS
MERA PHARMACEUTICALS
MILLENNIUM, A TAKEDA ONCOLOGY CO.
NAUTILUS BIOSCIENCES CANADA, INC.
NÉOVACS
NEUROBIOPHARM, INC. (PART OF NEPTUNE TECHNOLOGIES)
NEREUS PHARMACEUTICALS
OHR PHARMACEUTICALS
PACIRA PHARMACEUTICALS, INC.
PHARMAMAR
PHARMA MARINE USA, LLC
PHYCOSOURCE
PML APPLICATIONS, LTD.
PRIMEX EHF
PROLUME, LTD.
PRONOVA BIOPHARMA ASA
SEA RUN HOLDINGS
SEATTLE GENETICS, INC.
SIGMA-TAU PHARMACEUTICALS, INC.
STELLAR BIOTECHNOLOGIES
STRATEGRO INTERNATIONAL, LLC
TAIHO PHARMACEUTICALS
TEQUESTA BIOVENTURES
TRITON BIOPHARMA
TRIUS THERAPEUTICS
VERONA PHARMA, PLC
XENOME, LTD.
YAKULT HONSHA CO, LTD.
ZELTIA GROUP (GRUPO ZELTIA)
Chapter- 6: APPENDIX: RESOURCES

5. Table 28 : MARINE RESEARCH RESOURCES BY CATEGORY
Table 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRY
List of Tables
Summary Table : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS BY TYPE, THROUGH
2016
Table 1 : KEY DATES IN MARINE-DERIVED DRUG HISTORY
Table 2 : GROWTH IN THE INTEREST IN MARINE NATURAL PRODUCTS BASED ON THE
NUMBER OF PRODUCTS DESCRIBED IN SCIENTIFIC JOURNALS, 1999–2004
Table 3 : TOP 10 PHARMA IN SALES IN 2010
Table 4 : PHARMAMAR R&D PIPELINE IN THE U.S., 2011
Table 5 : MARINE-DERIVED DRUGS APPROVED AND IN LATE-STAGE DEVELOPMENT*, 2011
Table 6 : MARINE-DERIVED DRUGS/DRUG CANDIDATE’S MECHANISM OF ACTION
Table 7 : KEY MARINE-DERIVED PRODUCT LIBRARIES
Table 8 : KEY MARINE-DERIVED DRUG RESEARCH CANDIDATES: COMPOUNDS BY DRUG
TYPE
Table 9 : GLOBAL PHASE III PIPELINE FOR BREAST CANCER THROUGH 2016
Table 10 : GLOBAL PHASE III PIPELINE FOR BRAIN OR CNS CANCER, THROUGH 2016
Table 11 : GLOBAL PHASE III PIPELINE FOR BLADDER CANCER, THROUGH 2016
Table 12 : GLOBAL PHASE III PIPELINE FOR COLORECTAL CANCER, THROUGH 2016
Table 13 : GLOBAL PHASE III PIPELINE FOR HEAD AND NECK CANCER, THROUGH 2016
Table 14 : GLOBAL PHASE III PIPELINE FOR KIDNEY CANCER, THROUGH 2016
Table 15 : GLOBAL PHASE III PIPELINE FOR LEUKEMIA, THROUGH 2016
Table 16 : GLOBAL PHASE III PIPELINE FOR LIVER CANCER THROUGH 2016
Table 17 : GLOBAL PHASE III PIPELINE FOR LUNG CANCER THROUGH 2016
Table 18 : GLOBAL PHASE III PIPELINE FOR LYMPHOMA, THROUGH 2016
Table 19 : GLOBAL PHASE III PIPELINE FOR MULTIPLE MYELOMA, THROUGH 2016
Table 20 : GLOBAL PHASE III PIPELINE FOR OVARIAN CANCER, THROUGH 2016
Table 21 : GLOBAL PHASE III PIPELINE FOR PANCREATIC CANCER, THROUGH 2016
Table 22 : GLOBAL PHASE III PIPELINE FOR PROSTATE CANCER, THROUGH 2016
Table 23 : GLOBAL PHASE III PIPELINE FOR SARCOMA, THROUGH 2016
Table 24 : GLOBAL PHASE III PIPELINE FOR SKIN CANCER, THROUGH 2016
Table 25 : GLOBAL PHASE III PIPELINE FOR SOLID TUMORS, THROUGH 2016
Table 26 : GLOBAL PHASE III PIPELINE FOR STOMACH CANCER, THROUGH 2016
Table 27 : GLYCOMAR POLYSACCHARIDE CHARACTERIZATION SERVICES
Table 28 : MARINE RESEARCH RESOURCES BY CATEGORY
Table 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRY
List of Figures
Summary Figure : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS, 2010-2016
Figure 1 : THE TUNICATE ECTEINASCIDIA TURBINATE FROM WHICH YONDELIS
(TRABECTEDIN) FOR CANCER TREATMENT IS MADE
Figure 2 : MARINE SPECIES PER PHYLUM BASED ON WORMS
Figure 3 : APPROXIMATION OF KNOWN VERSUS POSSIBLE SPECIES WITHIN THREE PHYLA,
2011
Figure 4 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2011 AND 2016
Figure 5 : COMMERCIALIZED MARINE DRUGS*, 2010–2016
Figure 6 : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS* BY THERAPEUTIC
CATEGORY, 2009-2016

6. Figure 7 : COMMERCIALIZED MARINE DRUGS BY THERAPEUTIC AREA, 2011
Figure 8 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2016
Figure 9 : GLOBAL PHARMACEUTICAL DRUG SALES, 2010
Figure 10 : GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL SALES, 2010 AND 2016
Figure 11 : MARINE SAMPLE/MOLECULE CULTIVATION AND PROCESSING
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog